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Objective: Congenital hyperinsulinism (CHI) is a rare condition of hypoglycemia where
therapeutic options are limited and often complicated by side-effects. Omega-3-
polyunsaturated fatty acids (PUFA), which can suppress cardiac myocyte electrical activity,
may also reduce ion channel activity in insulin-secreting cells. PUFA supplements in com-
bination with standard medical treatment may improve glucose profile and may reduce
glycemic variability in diazoxide-responsive CHI.
Design: Open label pilot trial with MaxEPAR liquid (eicosapentaenoic and docosahexaenoic
acid) PUFA (3 ml/day for 21 days) in diazoxide-responsive CHI patients (https://eudract.ema.
europa.eu/, EudraCT number 201100363333).
Methods: Glucose levels were monitored pre-treatment, end of treatment, and at follow-
up by subcutaneous continuous glucose monitoring systems (CGMS) in 13 patients (7
girls) who received PUFA. Outcome measures were an improved glucose profile, reduced
glycemic variability quantified by a reduction in the frequency of glucose levels <4 and
>10 mmol/l, and safety of PUFA. All children were analyzed either as intention to treat
(n=13) or as per protocol (n=7).
Results: Mean (%) CGMS glucose levels increased by 0.1 mmol/l (2%) in intention to treat
and by 0.4 mmol/l (8%) in per protocol analysis (n=7). The frequency of CGMS <4 mmol/l
was significantly less at the end of treatment than in the pre-treatment period [556 (7%)
vs. 749 (10%)]. Similarly, the frequency of CGMS >10 mmol/l, was also less at the end of
treatment [27 (0.3%) vs. 49 (0.7%)]. Except for one child with increased LDL cholesterol,
all safety parameters were normal.
Conclusion: MaxEPAR was safe and reduced glycemic variability, but did not increase glu-
cose profiles significantly in diazoxide-responsive CHI. The supplemental value of PUFA
should be evaluated in a comprehensive clinical trial.
Keywords: congenital hyperinsulinism, hypoglycemia, clinical trial, omega-3-polyunsaturated fatty acids, diazoxide
BACKGROUND
Congenital hyperinsulinism (CHI) is the commonest cause of
severe hypoglycemia in children (1, 2) and is associated with
adverse neurodevelopmental morbidity in about a third of cases
Abbreviations: CGMS, continuous glucose monitoring systems; CHI, congenital
hyperinsulinism; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; KATP,
ATP-sensitive K+ channels; LDL, low density lipoprotein; PUFA, polyunsaturated
fatty acids.
(3). The treatment of hypoglycemia in CHI is complex and chal-
lenging. Medical therapy is limited to diazoxide as first line and
octreotide as second line choices for the long-term treatment of
CHI, with intravenous glucagon use limited to early intervention
in the majority of patients (1, 4, 5). However, both diazoxide and
octreotide are complicated by inefficacy and adverse effects (4–10).
Near total or subtotal pancreatectomy is an option in children who
do not respond to medical management. However, the incidence
of iatrogenic diabetes, requiring insulin treatment remains high in
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those who undergo a near total procedure (11). While novel treat-
ment options such as glucagon like peptide 1 antagonists have
been tested in older children with CHI, routine clinical applica-
tion is not yet advocated, pending further studies (12). Hence,
there is a significant need to develop further treatment options in
the medical management of CHI (13).
Purified fish oils, as food supplements or prescribed formula-
tions containing the polyunsaturated fatty acids (PUFA), eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA), have
been used in the prevention of cardiac arrhythmias following
acute myocardial injury (14–16). The mechanism of action of
these agents includes a suppression of electrical activity in cardiac
myocytes mediated by the inhibition of voltage-gated Na+ and
Ca2+ ion channels, which will prolong the relative refractory peri-
ods of the cardiac action potential and prevent cytosolic calcium
overload during ischemic events (17, 18). CHI involves the gen-
eration of inappropriate electrical activity in β-cells. This occurs
either as a direct consequence of mutations in the ATP-sensitive
potassium (KATP) channel genes or as a result of metabolopathies
leading to enforced KATP channel closure (1, 4, 19). Diazoxide
reduces transmembrane potentials in β-cells by binding to and
modulating KATP channel status (20), and this effect is utilized
in the medical therapy of CHI (1). However, diazoxide bind-
ing to KATP channels is incomplete (21) and can be associated
with some variability in glucose levels, particularly with illness
episodes and variation in nutrition. It is recognized that con-
ductance across KATP channels in animal models is subject to
slow oscillation (22), which may explain the observed variation
in diazoxide treatment response. Further, response to diazox-
ide therapy is not predictably dose dependent; there are case
reports of paradoxical hypoglycemia with diazoxide treatment
in children with CHI (23). Therefore, while patients on dia-
zoxide are responsive to treatment by demonstrating glycemic
stability to a safety fast (1, 5), minor glucose fluxes, both high
and low are expected, although occurring infrequently. Although
hyperglycemia is not a common cause for concern in the rou-
tine management of CHI, glucose intolerance in normal indi-
viduals following partial insulin inhibition with diazoxide has
been recognized (24). It is likely that children with CHI also
experience occasional hyperglycemia in response to treatment
with diazoxide, particularly during intercurrent illnesses. Fur-
ther, glucose-induced electrical activity in β-cells is likely to be
modulated by other cellular channel mechanisms, although spe-
cific models are yet to be determined (25, 26). We hypothe-
sized that PUFA may exert additional suppression of electrical
activity in insulin-secreting cells and that this may lead to a
further reduction in inappropriate insulin secretion in patients
with CHI. PUFA has an established satisfactory safety profile in
adults and children (27, 28) and its status as a food supplement
makes fish oil-derived PUFA a potentially attractive treatment
adjunct in children with CHI. Supplementing diazoxide with
PUFA in the treatment regimen of CHI patients may offer tighter
glycemic control and therefore potentially better long-term out-
comes. Here, we have reported for the first time, the supplemental
use of MaxEPAR on glycemic profile and glycemic variability in
diazoxide-responsive CHI.
MATERIALS AND METHODS
We aimed to investigate if the addition of PUFA improved glycemic
profile and reduced glycemic variability in children with CHI.
Only children who were responsive to diazoxide were chosen for
recruitment, this being a pilot trial of an experimental food sup-
plement with no previous treatment experience of PUFA in CHI
patients. Children between the ages of 6 months and 11 years,
with confirmed persistent CHI, and treated with diazoxide with
satisfactory glycemic stability were invited to participate in the
trial of purified PUFA. Diazoxide responsiveness was defined as
achieving euglycemia to a dose of <15 mg/kg/day, satisfactory
tolerance to a safety fast at discharge from hospital (1) using
age appropriate fasting periods, and >90% of home blood glu-
cose measurements within a range of 4–6 mmol/l, over a 1-month
period, with no symptoms or signs of neuroglycopenia. The pres-
ence or absence of a known CHI-related gene mutation did not
preclude participation in the trial, as there is no currently available
information regarding glycemic responsiveness to PUFA supple-
mentation in children with and without CHI mutations. The trial
was ethically approved with an ethics committee reference number
11/NW/0549 and European Union trial number 2011-003633-
33. Informed consent was obtained from parents of children
with CHI.
The primary outcome of the study was to demonstrate an
increase in glycemic profile with PUFA supplementation. This
being a pilot study, with no previous data, the increment in glu-
cose to achieve a satisfactory outcome following PUFA treatment
was not specified. However, as an estimate, the study protocol pro-
posed a sample number of 15 children to detect a mean glucose
increment of 1 mmol/l with 85% power, assuming a group stan-
dard deviation of 1 mmol/l. The study also evaluated glycemic
variability, quantified by the risk of developing hypoglycemia
before and after PUFA supplementation. While hypoglycemia was
defined as glucose<2.6 mmol/l, measurements with glucose levels
<4 mmol/l (i.e., below the normal glucose range of 4–6 mmol/l),
commensurate with trends to develop hypoglycemia detected by
in vivo sampling using continuous glucose monitoring (29, 30),
were also analyzed. Similarly, hyperglycemia was defined as glucose
>10 mmol/l, for the study cohort (31), with risk of hyperglycemia
being defined as glucose >6 mmol/l.
Children already established on diazoxide treatment (5–
12 mg/kg/day) were invited to participate in the trial (Figure 1).
These children had satisfactory glycemic stability defined by tol-
erance to an age appropriate fast, with no reported episodes of
symptomatic neuroglycopenia in the month preceding recruit-
ment to the trial. Further, their frequency of relatively low blood
glucose levels (<4.0 mmol/l) on home blood glucose monitoring
was less than once a week. Children on diazoxide who were less
stable than the above definition were excluded from participation
to the study, as they required dose adjustments and therefore their
recruitment to a pilot study would be inappropriate. A total daily
diazoxide dose <6 mg/kg/day was considered to be a low dose,
while higher values were considered as relatively high dosage.
Gastrostomy tube feeding was permitted at entry, provided that
tube feeding was initiated for feed intolerance, not for achieving
glycemic stability and that feeds were administered as boluses,
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at intervals of at least 4 h. The use of cephalosporins, warfarin,
or other anticoagulation was not permitted due to anticipated
adverse effects on coagulation and such treatment would lead to
withdrawal from the trial.
Purified fish oil (MaxEPAR liquid, Seven Seas Limited,
Kingston-upon-Hull, UK; Marketing authorization number:
PL01932/0003, 1.1 ml= 1 g; each gram containing 170 mg EPA
and 115 mg DHA) was administered in a dose of 3 ml/day (EPA
459 mg, DHA 310 mg/day) for a total of 21 days. The daily dose
was calculated to be similar to previous drug trial doses in adults
(14) and to those used in children (28). As this was a pilot trial,
and not a dose finding study, PUFA dose was not specified for
age or body weight. Investigation, monitoring, and treatment of
patients were performed as specified in Table 1. Parents were
FIGURE 1 | Participant flow diagram describing patient recruitment to
the PUFA pilot trial in children with CHI.
required to keep a daily food, activity logbook, and medication
compliance diary for each patient with twice daily blood glucose
measurements before breakfast and dinner, using the following
glucometers: GlucoMen LxPlus (Menarini Diagnostics, UK), One-
Touch®Ultra®2 (Lifescan, UK), and Accu-Chek® Aviva (Roche,
UK). All glucometers were calibrated as per manufacturers’ rec-
ommendation, prior to the start of the trial. Documented adher-
ence to the trial conditions, treatment dose, and the amount of
purified fish oil-derived PUFA consumed was monitored during
each study visit to ensure compliance. Parents were also required
to return empty medication bottles at the end of treatment
period.
Continuous glucose monitoring systems (CGMS) was used to
monitor subcutaneous glucose at frequent intervals to determine
glycemic control. CGMS glucose is recognized as a useful tool to
represent and compare glycemic trends over time (32, 33) and was
therefore utilized as the primary method to assess glycemic con-
trol in relation to PUFA supplementation. In addition, home blood
glucose monitoring, although infrequent in measurement (with a
minimal frequency of twice daily) was also utilized as a marker of
glycemic control. Blood glucose monitoring was performed four
times daily for the duration of CGMS monitoring. Blood glucose
monitoring frequency at other times was continued as per the
child’s usual home monitoring frequency, although a twice daily
frequency was set as a minimum requirement. Frequent labora-
tory blood glucose levels were not measured owing to the practical
and logistic difficulties of venous sampling in children. The iPro™
2 (Medtronic Limited, Watford, UK) CGMS device was inserted
subcutaneously at specified time periods before treatment, at the
end of treatment, and in the follow-up period to provide trends
in glycemic status. CGMS readings, recorded every 5 min, were
downloaded for analysis.
Adverse events were monitored at each visit to the treatment
center. Provisions were made to monitor serious adverse reactions
(SAR), whether expected SAR or suspected unexpected serious
adverse reactions (SUSAR). Criteria to stop the trial included new
safety data, or concerns from safety data (number and nature of
Table 1 | Investigation, monitoring, and treatment protocol for patients with CHI recruited to the trial, showing time, time periods, and
procedures in columns (BP, blood pressure).
Day Period Procedures
Day 1 Pre-treatment Consent form; baseline observations (heart rate and BP); 48 h subcutaneous continuous glucose monitoring; baseline
blood investigations (fasting blood glucose, insulin, lipids, liver function tests); education of parents regarding
administration of fish oil
Day 3 On-treatment Start 3 week trial of fish oil treatment
Day 10 On-treatment Baseline observations (heart rate and BP); blood investigations (fasting blood glucose, insulin, lipids, liver function tests);
monitoring of log book and diary
Day 23 End of treatment Baseline observations (heart rate and BP); repeat 48 h continuous glucose monitoring; blood investigations (fasting blood
glucose, insulin, lipids, liver function tests); monitoring of log book activity
Day 44 Follow-up Baseline observations (heart rate and BP); repeat 48 h continuous glucose monitoring; blood investigations (fasting blood
glucose, insulin, lipids, liver function tests); advice to continue diazoxide; monitoring of log book activity
For analysis, the following time periods represented the chronology of trial treatment: pre-treatment, on-treatment, end of treatment, and follow-up.
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SUSARs) or evidence from other studies. Data derived from this
study was analyzed by SPSS 20.0 (IBM©United States, 2011) using
paired t -tests for comparison of data between pre-treatment and
end of treatment periods. The statistical software R (R Foundation
for Statistical Computing, Austria, 2013) was used for graphical
representation and for construction of smoothed trajectories of
CGMS glucose profiles in the pre-treatment and end of treatment
periods (34).
RESULTS
Fourteen sets of parents and children with CHI were approached
to participate in the trial (Figure 1). Although parents of all 14 chil-
dren provided consent, 1 child withdrew assent and was excluded
from the study. Thirteen children (patient #1–13) (six boys, seven
girls) were recruited to the trial and received study drug, there-
fore constituting the intention to treat group. At entry to the
trial, the median (range) age of the children was 5.9 (1.0; 11.9)
years. The median (range) age at diagnosis of hypoglycemia was
1 (1; 750) day, with insulin levels of 9.0 (3.0; 20.0) mU/l when
diagnosed with CHI. Early neonatal diagnosis (age <7 days) was
noted in 8 (61%). No mutations were found in ABCC8/KCNJ11
in 10 (77%) children, while in 3 children, the following mutations
were found: paternally heterozygous KCNJ11 (n= 1, patient #13),
paternally heterozygous GCK (n= 1, patient #10), and HADH
(n= 1, patient #4). Positron emission and computed tomogra-
phy (PET–CT) scans using 6-l-18F-fluorodihydroxyphenylalanine
(18F DOPA) were performed in the child with a heterozygous
KCNJ11 mutation and in eight other children with no mutations,
as per local clinical protocol (13). All scans suggested non-focal
etiology. All recruited children were treated with diazoxide in a
dose of 8.3 (5.0; 12.0) mg/kg/day at the time of recruitment to
the study, and were responsive to treatment with no unaccept-
able adverse effects to consider alternative medical therapy. All
recruited children were managed at home with visits to the trial
center as per protocol.
Suspected unexpected serious adverse reactions were not
reported in any of the 13 children recruited to the trial. However,
in six children, protocol deviation was recorded in the follow-
ing aspects: duration of PUFA treatment less than (patient #3) or
beyond (patient #5, #10) 3 weeks, monitoring stopped due to con-
comitant infection (patient #7), home blood glucose not measured
(patient #2), and CGMS duration<48 h (patient #2, #13). There-
fore, pooled data from a total of seven children (three boys, four
girls) of median (range) 4.2 (1.4; 7.9) years were further analyzed
as per protocol.
GLYCEMIC STATUS IN RESPONSE TO PUFA SUPPLEMENTS
Continuous glucose monitoring system glucose levels, recorded
for all patents in intention to treat and per protocol analyses,
have been summarized in Table 2A. Overall, there was a small
(mean increase 0.10 mmol/l, 1.9%, p< 0.001) clinically insignif-
icant increase in CGMS glucose levels at the end of treatment
in intention to treat analysis. The increment was greater (mean
increase 0.40 mmol/l, 7.5%, p< 0.001) in per protocol analysis.
Individual CGMS responses for patients in intention to treat analy-
sis were variable, as shown by the spread of glucose levels around
the median value in Figure 2. Although CGMS glucose levels
Table 2 | (A) Mean (SD) pre-meal CGMS glucose levels (millimoles per
liter) have been shown for each time period: pre-treatment, end of
treatment, and follow-up, both in an intention to treat analysis
(n=13) and per protocol analysis (n=7). (B) Mean (SD) pre-meal
blood glucose levels (millimoles per liter) have been shown for each
time period: pre-treatment, on-treatment, end of treatment, and
follow-up, both in an intention to treat analysis (n=13) and per
protocol analysis (n=7).
Treatment
period
Intention to treat
(n=13)
Per protocol
(n=7)
Number of
readings
Mean (SD) Number of
readings
Mean (SD)
(A) CGMS glucose levels
Pre-treatment 7375 5.26 (1.28) 3930 5.29 (1.18)
End of treatment 7984 5.36 (1.14) 4307 5.69 (1.13)
Follow-up 8465 5.19 (1.35) 4219 5.45 (1.50)
(B) Blood glucose levels
Pre-treatment 140 5.44 (1.68) 78 5.41 (1.41)
On-treatment 862 5.29 (1.48) 422 5.49 (1.65)
End of treatment 144 5.54 (1.54) 79 5.79 (1.69)
Follow-up 693 5.35 (1.56) 381 5.29 (1.36)
CGMS glucose was not measured in the on-treatment period, unlike blood
glucose levels.
FIGURE 2 | Median, interquartile range, and ±2 SD values for CGMS
glucose (millimoles per liter) have been summarized for all patients
receiving PUFA supplements in intention to treat analysis.
remained variable at all three treatment periods, the variability
was less at the end of treatment as shown by the lower coefficient
of variation (representing a normalized measure of dispersion)
in Figure 3. The amalgamated, smoothed trajectories of CGMS
glucose profiles showed an overall improvement in per protocol
analysis (Figure 4). An individual example of a positive response
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FIGURE 3 | Coefficient of variation (CV) (%) in CGMS glucose levels
shows a reduction at the end of treatment in intention to treat
analysis, indicating reduced variability in glucose profiles following
treatment with PUFA.
FIGURE 4 | Composite graph of smoothed trajectories of CGMS
glucose profiles for all patients analyzed per protocol (n=7) in the
pre-treatment (black line) and end of treatment (red line) periods show
overall improvement in glycemic control following PUFA treatment.
Individual glucose values have not been shown for clarity.
to PUFA supplement is shown in Figure 5. Pre-meal blood glu-
cose levels, summarized in Table 2B, were unchanged in intention
to treat (mean increase 0.1 mmol/l, 1.8%, p= 0.59) and increased
minimally in per protocol analyses (mean increase 0.38 mmol/l,
7.0%, p= 0.13).
At the time of PUFA supplementation, six children were treated
with low dose diazoxide (dose <6 mg/kg/day). The effect of low
dose diazoxide on CGMS glucose levels following PUFA supple-
mentation was analyzed by a two-way ANOVA model (adjusted
R2= 0.03, p< 0.001). In addition to the effects of PUFA on glu-
cose, low dose diazoxide was independently associated with a
higher mean (SD) glucose level than high dose diazoxide [5.4 (1.2)
FIGURE 5 | Mean (95% confidence intervals) CGMS levels at
pre-treatment, end of treatment, and follow-up time periods in patient
#4, who carries a HADH mutation. Following treatment with PUFA, the
patient’s CGMS glucose increased significantly, with reduction after
treatment was discontinued.
vs. 5.2 (1.0),p< 0.001]. The interaction of PUFA and low dose dia-
zoxide was also associated with a higher glucose level (p< 0.001),
suggesting that PUFA supplementation in children on low dose
diazoxide may be more beneficial in improving the glycemic profile
than those receiving relatively higher dosage.
VARIABILITY OF GLYCEMIC STATUS IN RESPONSE TO PUFA
SUPPLEMENTS
The frequency of CGMS glucose >10 mmol/l, indicating hyper-
glycemia, was lower at end of treatment compared to the pre-
treatment period, in intention to treat analysis [27 (0.3%) vs.
49 (0.7%), p= 0.004] (Figure 6A). However similar results were
not replicated in per protocol analysis, as hyperglycemia was not
observed in the pre-treatment period. Similarly, the frequency of
blood glucose >10 mmol/l was also less at the end of treatment
than at pre-treatment (Figure 6B), although the difference was
not statistically significant [2 (1.4%) vs. 5 (3.6%), p= 0.27], a
reflection of the relatively small sample size. The frequency of
CGMS glucose >6 mmol/l reflecting the risk of hyperglycemia
was also tested, but was similar between pre-treatment and end of
treatment periods.
The frequency of CGMS glucose <4 mmol/l was significantly
less at the end of treatment than in the pre-treatment period [556
(7.0%) vs. 749 (10.1%), p< 0.001] in intention to treat analy-
sis (Figure 7A) and also in per protocol analysis [105 (2.4%) vs.
343 (8.7%), p< 0.001]. In the follow-up period, the frequency
of CGMS glucose <4 mmol/l rebounded to exceed that in the
pre-treatment period. Although not significantly different, the
frequency of blood glucose <4 mmol/l was also lower at the
end of treatment (Figure 7B) [7 (4.9%) vs. 14 (10%), p= 0.09].
In contrast, the frequency of CGMS glucose <3.5 mmol/l as an
alternative measure of the risk of hypoglycemia was not lower at
the end of treatment.
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FIGURE 6 |The frequency (%) of measurements with a glucose
level >10 mmol/l has been shown for each treatment period for
both blood glucose (black filled bars) (B) and CGMS glucose (gray
bars) (A) in intention to treat analysis. There was a reduction in the
frequency of blood glucose >10 mmol/l from 3.6% (pre-treatment)
to 1.4% (end of treatment), p=0.27. Similarly, the frequency
of CGMS glucose >10 mmol/l was reduced from 0.7 to 0.3%,
*p=0.004.
FIGURE 7 |The frequency (%) of measurements with a glucose
level <4 mmol/l has been shown for each treatment period for
both blood glucose (black filled bars) (B) and CGMS glucose (gray
bars) (A) in intention to treat analysis. There was a reduction in the
frequency of blood glucose <4 mmol/l from 10% (pre-treatment)
to 4.9% (end of treatment), p=0.09. Similarly, the frequency
of CGMS glucose <4 mmol/l was reduced from 10.1 to 7%,
*p<0.001.
ADVERSE EFFECT PROFILE WITH PUFA SUPPLEMENTS
Although blood and CGMS glucose levels >10 mmol/l were
recorded at the end of treatment, no child presented with fea-
tures of persistent hyperglycemia or symptoms to suggest diabetes.
Fasting glucose, insulin, and insulin resistance measured by the
HOMA-IR index (Table 3) were not different between the start
and end of treatment. Similarly, there were no differences in serum
alanine transaminase or albumin levels, representing satisfactory
liver function. However, serum cholesterol was elevated in one
child (pre-treatment 5.1 mmol/l, end of treatment 5.7 mmol/l,
follow-up 6.2 mmol/l), which remained elevated (6.7 mmol/l)
3 months after completion of PUFA treatment. In this child, there
was a history of familial LDL hypercholesterolemia, although LDL
cholesterol levels were within the normal range. It was not pos-
sible to convincingly exclude hypercholesterolemia, as a PUFA
related side effect and it was therefore reported as an adverse
event. Overall, total and LDL fractions of serum cholesterol were
elevated after treatment, although remaining within the normal
range (Table 3). In contrast, there was no difference in serum
triglyceride levels.
DISCUSSION
We report the first pilot trial of the use of supplemental purified
PUFA in the treatment of CHI. In this open label, phase 2 trial,
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Table 3 | Median (interquartile range) pre-meal markers of insulin
sensitivity, liver function, and lipid profile has been shown for all
patients.
Pre-treatment End of
treatment
pValue for
difference
Insulin (mU/l) 1.7 (2.1) 1.6 (3.4) 0.66
Glucose (mmol/l) 4.5 (0.7) 4.5 (0.6) 0.73
HOMA-IR 0.32 (0.53) 0.32 (0.71) 0.89
ALT (U/l) 17.0 (10.0) 18.0 (17.0) 0.45
Albumin (g/dl) 42.0 (4.0) 40.0 (4.0) 0.96
Cholesterol (mmol/l) 4.1 (1.0) 4.2 (0.7) 0.01*
LDL cholesterol (mmol/l) 2.2 (0.8) 2.7 (0.4) 0.009*
HDL cholesterol (mmol/l) 1.5 (0.5) 1.32 (0.6) 0.55
Triglyceride (mmol/l) 0.6 (0.3) 0.8 (0.4) 0.10
The difference of levels between pre-treatment and end of treatment periods
has been assessed by Wilcoxon tests for paired samples. Total and LDL choles-
terol levels were increased by a significant (*) margin at the end of treatment,
particularly noted in patient #8, although within the normal range.
although fish oil-derived PUFA supplements given to a group of
children with stable glycemic status did not increase CGMS or
blood glucose levels by a clinically significant margin, there was
significant reduction in the risk of developing both hypoglycemia
and hyperglycemia at the end of treatment period, suggesting
reduced glycemic variability. There was variability in the glu-
cose response between patients, with some patients responding
with a greater increment in glucose levels than others. In one
patient with the HADH mutation, there was brisk glycemic incre-
ment, suggesting that PUFA may be more beneficial in specific
forms of CHI, such as those due to lipid disorders. No signifi-
cant adverse effects of supplementation were noted, except for one
patient in whom hypercholesterolemia was observed. It is possi-
ble that familial hypercholesterolemia may have been present in
this patient, although the possibility of DHA induced LDL hyper-
cholesterolemia cannot be excluded, particularly as total and LDL
cholesterol levels were elevated following PUFA treatment (35, 36).
Results from several studies have shown that PUFA increases
fasting glucose concentrations in people with type 2 diabetes mel-
litus and control groups (37–39) and that this might occur by
decreasing the sensitivity of pancreatic β-cells to glucose (40). The
satisfactory safety profile in several studies in adults and children
(14, 27, 28) and its status as a food supplement makes fish oil-
derived PUFA an attractive treatment adjunct to achieve greater
glycemic stability in children with CHI. In our study, the primary
objective of increased glycemic response was not achieved and the
extent of glucose increment observed was lower than hypothesized
in the trial protocol. This may have been due to several factors,
including small sample size, low dose and duration of PUFA, age
differences, and variability in diazoxide dose. However, a small
but positive upward trend was noted, particularly in longitudi-
nal analysis. The magnitude of glucose response was greater in
those on lower doses of diazoxide, suggesting a differential PUFA
response with diazoxide sensitivity. While this finding may sug-
gest greater benefit in a select group of patients, the results should
be tested in a larger cohort to minimize small sample bias and
variability within the cohort.
It is possible that PUFA does not induce hyperglycemia in the
basal state while glycemic stability is already achieved, but reduces
the risk of developing hypoglycemia. From our study, it appears
that PUFA may reduce large fluxes of glucose, both high and low,
thereby achieving a more physiological profile in diazoxide treated
patients with CHI. The trend to a decrease in the frequency of
glucose <4 mmol/l was similar between CGMS and blood glu-
cose measurements and consistent for intention to treat and per
protocol analyses. In contrast, the reduction in frequency of hyper-
glycemia was not consistent between intention to treat and per
protocol analyses, which may suggest a greater effect of PUFA in
reducing the risk of hypoglycemia, but not hyperglycemia. The fre-
quency of hyperglycemia was also dissimilar between blood and
CGMS measurements. This may be due to CGMS measurements
being taken continuously, while the majority of blood glucose lev-
els correlated to mealtimes only. The differences in frequency of
measurement between the two methods and the possibility that
CGMS may be less sensitive in the detection of hypoglycemia than
blood glucose monitoring (41) may also explain the variation.
For a future trial, a prolonged duration of CGMS for each period
related to treatment may be useful.
We did not address the mechanisms of action of the purified
omega-3 acid ethyl esters on isolated islets from CHI patients
in this study. However, since PUFA leads to a shift in voltage
dependence of inactivation in the hyperpolarizing direction for
voltage-gated Ca2+ and Na+ channels in cardiac myocytes (42, 43),
a similar shift in the voltage dependence of calcium channel inac-
tivation in pancreatic β-cells would be expected to reduce hypo-
glycemia by attenuating Ca2+ influx-dependent insulin secretion.
In conjunction with diazoxide, PUFA may potentiate membrane
stabilization in β-cells, leading to an overall decrease in glycemic
variability; however, such a mechanism remains unproven and
therefore speculative.
As this was a pilot study in a rare condition, the number of
children with CHI recruited to the trial were relatively few. Not
all children in the trial adhered strictly to the protocol. We have
therefore adjusted our results to include both intention to treat
and per protocol analyses. The study was designed to measure
subcutaneous glucose levels before treatment and at the end of
treatment, but not during treatment. In the treatment phase, only
blood glucose levels by home monitoring devices were recorded.
As an alternative, CGMS monitoring could have been utilized;
however, the frequent multiple insertion of subcutaneous needle
devices was deemed intrusive and impractical and therefore not
incorporated in the study design.
We did not standardize the meter used for home glucose
monitoring, which may have introduced variability. It is widely
recognized that home blood glucose monitoring devices can be
technically unreliable, particularly at low values (44). Therefore,
our results would have been more accurate had we monitored more
frequently and used a more robust method for measuring blood
glucose, such as a reliable point of care testing or a formal labora-
tory analysis. The latter would, however, have required prolonged
hospital admission and generated undue distress in individuals
and introduced a bias in the results. In contrast to blood glucose
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monitoring, CGMS readings were more numerous and therefore
captured continuous trends over longer periods of time.
Our data show that PUFA brings about a reduction in the
tendency to develop hypoglycemia and this is an important obser-
vation in children who are already receiving moderately large doses
of diazoxide. In this situation, the addition of PUFA may bring
about greater glycemic stability, while perhaps allowing a diazox-
ide dose reduction to minimize adverse effects of this drug. In
those on larger doses of diazoxide with episodic hypoglycemia,
PUFA may tighten glycemic control, thereby preventing second
line therapy with injectable somatostatin analogs. In our cohort,
we have shown that PUFA treatment for patients on low dose
diazoxide was associated with higher glucose levels. Therefore,
PUFA treatment may aid withdrawal of diazoxide in those on
minimal treatment. Whether PUFA supplementation reduces the
frequencies of hypo and hyperglycemia at lower thresholds need
to be tested in appropriately powered and larger multicentered
cohorts. Initial results from the pilot trial involving relatively
small number of patients are encouraging and provide a basis
on which to conduct a comprehensive clinical trial investigating
the utility of PUFA supplements in all patients treated medically
for CHI. In such a trial, alternative forms of PUFA, for exam-
ple, a predominantly EPA containing fatty acid (AMR101) with
lesser risk of increasing LDL cholesterol (35, 36, 45) may be
considered.
CONCLUSION
In our pilot trial, we observed that purified PUFA was safe and
reduced glycemic variability, i.e., the risk of both hypoglycemia
and hyperglycemia in children with diazoxide-responsive CHI.
Although overall glucose levels were not increased significantly,
glycemic increment was significant in some children, suggesting
positive individual glycemic responses to PUFA. The mechanisms
of action associated with reduction in hypo and hyperglycemia
remain undetermined, although stabilization of inappropriate ion
channel activity in pancreatic β-cells may be involved. Based on
our initial results, PUFA may be considered as an additional thera-
peutic option to tighten glycemic control in diazoxide treated CHI
patients. Functional studies and a larger, more comprehensive trial
are required to fully investigate the value of PUFA as a treatment
adjunct for CHI.
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